Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 1,902 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Prescription Medications in Marijuana Users

NCT00893074
Conditions
Marijuana Abuse
Interventions
Dronabinol 30mg/day, Dronabinol 60mg/day, Dronabinol 120mg/day, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Rifapentine on Raltegravir

NCT00809718
Conditions
Healthy
Interventions
Raltegravir and rifapentine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Carcinoma, Renal Cell
Interventions
GW786034 (pazopanib), Probe drugs
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Healthy
Interventions
modafinil, methylphenidate, lorazepam, placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Conditions
Schizophrenia
Interventions
placebo, SEP-363856, metformin
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Oakland Park, Florida • Marlton, New Jersey
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Danicamtiv, Midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
Conditions
RSV Infection
Interventions
EDP-938, Cyclosporine, Prednisone
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo insulin icodec, Insulin degludec, Placebo insulin degludec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
94
States / cities
Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 81 more
Completed Not applicable Interventional Results available

Osteopathic Otitis Media Research Study

NCT00520039
Conditions
Otitis Media With Effusion
Interventions
osteopathic manipulative medicine (OMM)
Procedure
Lead sponsor
West Virginia School of Osteopathic Medicine
Other
Eligibility
6 Months to 2 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Biddeford, Maine • Lewisburg, West Virginia
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • New York, New York + 2 more
Conditions
Fragile X Syndrome
Interventions
Baclofen, Memantine, Roflumilast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Cystinuria
Interventions
Tiopronin 1g per day, Tiopronin 2g per day, Tiopronin 3g per day
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Dry Eye
Interventions
Systane Lubricant eye drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Osteoporosis
Interventions
SB-751689 oral tablets (400 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Port Orange, Florida
Conditions
Healthy
Interventions
Opevesostat, Prednisone, Fludrocortisone acetate, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Not listed Not applicable Interventional Accepts healthy volunteers

Sorrel 25R Injector - Sorrel Clinical Study Protocol

NCT05221333
Conditions
Injection Site, Injection Site Reaction, Injection Site Irritation
Interventions
Sorrel Wearable Injector
Device
Lead sponsor
Eitan Medical
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Tacrolimus

NCT01535547
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Tacrolimus, Healthy Volunteers
Interventions
isavuconazole, tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Human Volunteers
Interventions
PF-04937319 / ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Healthy
Interventions
Danuglipron, Cyclosporine, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
ketoconazole, casopitant 100 mg, Casopitant 50 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Pain, Abuse, Drug
Interventions
Oxycodone, Cannabis (THC:CBD = ~ 1:0), Cannabis (THC:CBD = ~ 0:1), Cannabis (THC:CBD = ~ 1:1), Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 53 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

Diurnal Variation of Plasminogen Activator Inhibitor-1

NCT00515021
Conditions
Metabolic Syndrome X
Interventions
Eplerenone (Morning), Eplerenone (Night-time)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Electronic Cigarette Use
Interventions
RELX ENDS Tobacco Flavor, RELX ENDS Menthol Flavor, RELX ENDS Tobacco and Menthol Flavors
Other
Lead sponsor
Cheerain HK Limited
Industry
Eligibility
22 Years to 65 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Bentonville, Arkansas • Lexington, Kentucky • Springfield, Missouri + 2 more
Conditions
Healthy Volunteers
Interventions
Itopride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota